Supplementary Materials

Table of Contents

Supplementary Table 1: Variants associated with waist-to-hip ratio adjusted for body mass index (WHR_{adjBMI}) in the discovery genome**wide analysis of rare non-synonymous variants.**

Analyses are from 450,562 European ancestry individuals. Genomic coordinates according to human genome reference sequence hg38.

* Adjusting for conditionally-independent index variants highlighted in the joint conditional model (see Supplementary Table 3 for list of index variants at loci where fine-mapping supported causal role of these variants and Supplementary Table 4 for other loci).

‡ Variants in addition to the one of the sex-combined primary analysis which were identified in a secondary analysis in 244,478 women from the UK Biobank study $(p<5\times10^{-8})$.

Abbreviations: SE, standard error; WHR, waist-to-hip ratio; BMI, body mass index; SD, standard deviation.

Supplementary Table 2. a. Correlation between the UK Biobank WES data and the genotype data for rare nonsynonymous variants with a minor allele frequency (MAF) between 0.1% - 0.5% in overlapping samples. b. Box plot of rare allele concordance between the UK Biobank WES data and the genotype data for rare nonsynonymous variants with a MAF between 0.1% - 0.5% in overlapping samples.

a. b.

Supplementary Table 3: a. Conditionally independent index variants and fine-mapping at the *CALCRL***,** *PLIN1***,** *PDE3B* **and** *ACVR1C* **loci.** Analyses are from 450,562 European ancestry individuals. Beta and standard errors are in standardized units of BMI-adjusted WHR per copy of the effect allele. Genomic coordinates according to human genome reference sequence GRCh38**. b. Formal conditional analyses at the** *CALCRL, PLIN1, PDE3B* **and** *ACVR1C* **loci.** Formal conditional analyses were conducted using individual-level genotype data in a subset of 350,721 unrelated European ancestry participants of UK Biobank. Because this is a subset of the discovery study, associations estimates differ from those presented in Supplementary Table 1.

* Adjusting for conditionally-independent index variants highlighted in the joint conditional model.

‡ Variant identified in the genome-wide scan of rare nonsynonymous variants.

Abbreviations: SE, standard error; SD, standard deviation; PPA, posterior probability of association.

b.

Supplementary Table 4: Conditionally-independent index variants at the *ABHD15, PYGM, PLCB3 and FNIP1* **regions.**

Conditional analyses estimated the association of each index variant while adjusting for all other index variants at the region. Index variants were selected using a joint meta-analysis model with GCTA (1).

 \dagger Identified in a secondary analysis in 244,478 women from the UK Biobank study ($p \leq x 10^{-8}$).

Supplementary Table 5: STAAR-O (2) gene-based results for genes discovered in the single variant analysis.

Abbreviations: pLOF, predicted loss of function; Pval, STAAR-O p-value; Beta, effect size; SE, standard error.

Supplementary Table 6: Significant gene-based results from the exome-wide scan for WHR_{adjBMI}.

Abbreviations: pLOF, predicted loss of function; MAF, minor allele frequency; Pval, STAAR-O p-value; Beta, effect size; SE, standard error; RR, reference/reference genotype; RA, reference/alternate genotypes; AA, alternate/alternate genotypes.

Supplementary Table 7: Sex-specific results for gene-based analysis.

Abbreviations: pLOF, predicted loss of function; P_sexdiff, p-value for the significance of the difference in women and men beta values; Pval, STAAR-O p-value; Beta, effect size; SE, standard error; RR, reference/reference genotype; RA, reference/alternate genotypes; AA alternate/alternate genotypes.

Supplementary Table 8: Quality control measurements for variants included in the refined gene-based tests and single marker association results for all included variants.

[Excel file: SupplementaryTable8_WHRadjBMI.xlsx]

Supplementary Table 9: a. Summary statistics for quantitative traits from gene-based association analyses in sex-combined, women-only and male-only data. b. Summary statistics for binary traits from gene-based association analyses in sex-combined, women-only and maleonly data. Details for all phenotypes and are given on Supplementary Table 12.

[Excel file: SupplementaryTable9_WHRadjBMI.xlsx]

Abbreviations: pLOF, predicted loss of function; Pval, STAAR-O p-value for phenotypic traits in Supplementary Table 9a and generalized linear model for binary traits Supplementary Table 9b; Beta, effect size; SE, standard error; Beta_LCI, lower 95% confidence interval for effect size in; Beta_UCI, upper 95% confidence interval for effect size; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Supplementary Table 10: a. Lookup from Type 2 Diabetes Knowledge Portal for type 2 diabetes. Seven different masks were applied to filter the variants used in the association analysis: LofTee (predicted loss of function); 5/5 (predicted deleterious by 5 methods); 16/16 (predicted deleterious by 16 methods); 5/5 + LofTee LC (predicted deleterious by 5 methods, plus LofTee low confidence), 5/5 + 0/5 1% (variants predicted deleterious by 5 methods, plus variants with minor allele frequency < 1% that are not predicted to be deleterious by any of 5 methods); $5/5 + 1/5$ 1% (variants predicted deleterious by 5 methods, plus variants with minor allele frequency < 1% that are predicted to be deleterious by 1 of 5 methods); and 11/11 (predicted deleterious by 11 methods). Rows in bold have P-value ≤ 0.05 . Accessed from<https://t2d.hugeamp.org/> on 02/09/2021. **b. Lookup from AstraZeneca PheWAS Portal (3) for type 2 diabetes, non-insulin-dependent diabetes mellitus (Union#E11#E11) and chronic ischaemic heart disease (Union#I25#I25).** The variant categories used in collapsing models are provided in the parentheses in 'Collapsing Model' column. Rows in bold have P-value ≤ 0.05 . Accessed fro[m https://azphewas.com/](https://azphewas.com/) on 02/09/2021.

b.

Abbreviations: QV, qualifying variant; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval; NA, not available.

Supplementary Table 11: Leave one out analysis results for the most significant single variant in significant genes.

Abbreviations: pLOF, predicted loss of function; chr, chromosome; pos, position (b38); MAF, minor allele frequency; Pval, STAAR-O p-value; Beta, effect size; SE, standard error; RR, reference/reference genotype; RA, reference/alternate genotypes; AA alternate/alternate genotypes.

Supplementary Table 12. Phenotypes used for phenotypic associations in UK Biobank. Sex (for sex-combined analyses), sequencing batch (50K vs. 150K), genotyping array, and 10 genetic principal components were included as covariates in association analyses.

Abbreviations: BMI, body mass index; HDL high-density lipoproteins; LDL low-density lipoproteins; RB-INV, rank-based inverse normal transformation; NA, not available.

Supplementary Figure 1: Regional association plots of the overall and statistically-decomposed signals at the *CALCRL***,** *PLIN1***,** *PDE3B* **and** *ACVR1C* genes. Plots were drawn using LocusZoom (4). Joint meta-analysis models using GCTA (1) were used at each locus to assess how many independent signals were present. Then, at each locus each signal was statistically-decomposed from others by estimating associations of all variants in the region adjusted for all other index variants at the region. Fine-mapping of each signal was performed using a Bayesian approach (5).

Supplementary Figure 2: Association of the significant genes with other body fat distribution or cardiometabolic trait related phenotypes in UK Biobank for (a) continuous phenotypes and (b) binary phenotypes. There was no rare predicted loss of function variant carriers for *INSR* in coronary heart disease (CHD) cases in women-only analyses. Abbreviations: pLoF, predicted loss of function; OR, odds ratio; WHRadjBMI; waist-to-hip ratio adjusted for body mass index; BMI, body mass index; TG, triglycerides; HD; high density lipoprotein, LDL low-density lipoprotein; TG/HDL, triglyceride to high density lipoprotein ratio; T2D, type 2 diabetes; CHD, coronary heart disease.

b.

Supplementary Note 1: Genomic context analyses at the *PLIN1***,** *ACVR1C***,** *PDE3B* **and** *CALCRL* **loci.**

Fine-mapping analyses provided strong statistical evidence for the causal association of rare nonsynonymous variants of *CALCRL, PLIN1, PDE3B* and *ACVR1C.*

At *PLIN1*, there was evidence of only one signal led by the rare p. L90P variant (rs139271800; Supplementary Figure 1), which was the only variant in the 99% credible set (PPA>99%; Supplementary Table 3).

At *ACVR1C*, there was evidence of three distinct signals (Supplementary Figure 1, Supplementary Table 3). The rare p.I195T variant led one of the secondary signals at this region and was the only variant in the 99% credible set (PPA>99%; Supplementary Table 3). In addition, the primary signal at this region was led by a low-frequency missense variant in *ACVR1C* (rs55920843, p.N150H), which also had the highest posterior probability in fine-mapping of this signal (PPA>99%; Table 1). Hence, fine-mapping of conditionally-independent signals at this locus converges on *ACVR1C* as causal gene for body fat distribution and p.I195T and p.N150H as causal variants for the respective association peaks.

At *PDE3B*, there was evidence of three signals, the strongest of which was led by the rs150090666 p.R783X nonsense variant in *PDE3B*, which was the only variant in the 99% credible set (PPA>99%; Supplementary Figure 1, Supplementary Table 3).

At *CALCRL*, there was evidence of two conditionally-independent signals (Supplementary Figure 1, Supplementary Table 3), led by the rs10177093 common variant and by the rare p.L87P variant, respectively. Fine-mapping at the latter signal yielded a 99% credible set including only two variants, rs61739909 (*CALCRL* p.L87P, posterior probability of casual association [PPA]=51%) and rs180960888 (intronic to *CALCRL*, PPA=48.5%). Hence, p.L87P is the most likely causal variant and *CALCRL* the most likely causal gene for this signal.

Supplementary Note 2: Genomic context analyses at the *ABHD15***,** *PYGM, PLCB3* **and** *FNIP1* **loci.**

In the main analysis, we found associations of rare nonsynonymous variants in *ABHD15* and *PYGM* for which genomic context analyses were not consistent with a causal association. At *ABHD15*, conditional analyses revealed two distinct association signals tagged by the rs62070804 and rs561089333 indexvariants respectively (Supplementary Table 4). The rare nonsynonymous rs141385558 p.G147D variant was not among these index variants and its association was greatly attenuated after adjusting for the two independent index variants ($p_{conditional}$ =0.00019; Supplementary Table 1). At *PYGM*, there was a complex association pattern with evidence of up to 12 distinct signals (Supplementary Table 4). The rare nonsense rs116987552 p.R50X variant was not among these 12 index variants and its association was greatly attenuated after adjusting for these 12 index variants (*pconditional*=0.00037; Supplementary Table 1). In the secondary analyses, we found associations of rare nonsynonymous variants in *PLCB3* (both in experimentlevel p-value and sex-specific analyses) and *FNIP1* (sex-specific analyses) for which genomic context analyses were not consistent with a causal association. At *PLCB3*, there was evidence of up to ten independent signals (Supplementary Table 4) but the p.V806I variant was not among those and adjusting for the conditionally-independent index variants greatly attenuated its association (*pconditional*>0.10; Supplementary Table 1). At *FNIP1* there was evidence of only one signal but the p.R518Q missense variant was not the lead variant (Supplementary Table 4). Adjusting for the lead variant attenuated the signal (*pconditional*=3.8×10-7 ; Supplementary Table 1) and the variant had low posterior probability in the finemapping analysis (PPA=8.7%).

Supplementary Note 3: Predictions regarding the variants identified through single marker analysis.

PDE3B p.R783X Phosphodiesterase 3B

ACVR1C p.I195T Activin A Receptor Type

1C

Phosphodiesterase 3B is a membrane bound phosphodiesterase highly expressed in adipocytes, where it has been implicated in terminating intracellular lipolysis in response to insulin by degrading cyclic adenosine monophosphate (12). Phosphodiesterase 3B null mice manifest enhanced intracellular lipolysis, lower fat mass but higher insulin resistance (13). The premature stop codon generated by p.R783X falls within the proximal half of the catalytic domain of phosphodiesterase 3B, removing most of its Mg2+ binding site (*Inset Figure 3*). Hence, this rare null variant, associated in our human genetic studies with lower waist-to-hip

ratio, higher levels of peripheral adiposity and lower blood pressure and triglycerides is expected to result in a loss of catalytic function of phosphodiesterase 3B. If the protein is expressed, it could be embedded in the membrane through its intact N-terminal 6 membrane spanning domains and impair the phosphodiesterase 3B signalling complex (14) in a dominant- negative manner. Therefore, our data provide evidence of causal link between the loss of phosphodiesterase 3B function and greater peripheral fat, more favourable fat distribution and lower blood pressure

and atherogenic lipids in humans. The effect size of this null allele on waist-to-hip ratio is over 6-fold greater than that of the strongest alleles found in GWAS of common variants (15).

Inset Figure 3. Structure of the catalytic domain of PDE3B (Protein Data Bank coordinates 1SO2 (16)) with an inhibitor in the active site (Protein Data Bank coordinates $1ISO2((17))$). The mutation R783X removes the protein part highlighted in grey. The N-terminus at the top of the figure is preceded by a 6 trans membrane helical domain. Inhibitor and active site residues are in ball and stick representation and the two blue balls indicate Mg^{2+} ions.

The Activin A Receptor Type 1C is type I member of the family of transforming growth factor beta receptors transmitting signals from extracellular ligands to nuclear transcription. ACVR1C downregulates the key fat storage and glucose metabolism regulator peroxisome proliferatoractivated receptor gamma (18). ACVR1C inhibits β-adrenergic signalling, mitochondrial biogenesis, lipid oxidation, and intracellular lipolysis in adipocytes (18). The *Inset Figure 4* shows a structural model of the intracellular part of ACVR1C. It can be seen that I195 forms a hinge between the N-terminal regulatory GS-domain and the kinase. Its side chain is tightly packed against both the kinase and the GS-domain. The serine/threonine epitope in the phosphorylation loop of the GS-domain is wedged in the active site between the kinase N- and C- lobes blocking access to the active site. Upon activation (phosphorylation), the GS-domain liberates the active site and interacts with its SMAD protein substrates. I195 is expected to be involved in any mutual GS- and kinase domain movement. Its side chain is buried in a hydrophobic environment and the change from aliphatic to polar residue should be significant. I195 is strictly conserved in all orthologues and in most metazoan paralogues including the 6 other human ones (*Inset Figure 5*). The rare replacements by different aliphatic amino acids (L, V) are very conservative. The mutation may influence kinase regulation as well as interaction with SMADs.

Inset Figure 4. Model of ACVR1C stabilized in its inactive conformation built according to the structure of TGFBR1 (Protein Data Bank coordinates 1B6C (19)). The N- terminus pointing to the membrane is on the top. The kinase domain is colored in blue, its N- and C-lobes distinguished in light and dark with the catalytic side- chains displayed in ball and stick and the activation loop in yellow. The regulatory GS-domain is in green with the phosphorylation epitope in orange and the alpha carbons of the residues to be phosphorylated upon activation highlighted by balls. The mutated L195 in ball and stick and space filling representation is in red.

REFERENCES

1. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88(1):76-82.

2. Li X, Li Z, Zhou H, Gaynor SM, Liu Y, Chen H, et al. Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nat Genet. 2020;52(9):969-83.

3. Wang Q, Dhindsa RS, Carss K, Harper AR, Nag A, Tachmazidou I, et al. Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature. 2021.

4. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26(18):2336-7.

5. Maller JB, McVean G, Byrnes J, Vukcevic D, Palin K, Su Z, et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet. 2012;44(12):1294-301.

6. Brasaemle DL, Subramanian V, Garcia A, Marcinkiewicz A, Rothenberg A. Perilipin A and the control of triacylglycerol metabolism. Mol Cell Biochem. 2009;326(1-2):15-21.

7. Granneman JG, Moore HP, Krishnamoorthy R, Rathod M. Perilipin controls lipolysis by regulating the interactions of AB-hydrolase containing 5 (Abhd5) and adipose triglyceride lipase (Atgl). J Biol Chem. 2009;284(50):34538-44.

8. Gandotra S, Lim K, Girousse A, Saudek V, O'Rahilly S, Savage DB. Human frame shift mutations affecting the carboxyl terminus of perilipin increase lipolysis by failing to sequester the adipose triglyceride lipase (ATGL) coactivator AB-hydrolase-containing 5 (ABHD5). J Biol Chem. 2011;286(40):34998-5006.

9. Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med. 2011;364(8):740-8.

10. Sztalryd C, Brasaemle DL. The perilipin family of lipid droplet proteins: Gatekeepers of intracellular lipolysis. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(10 Pt B):1221-32.

11. Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17-26.

12. DiPilato LM, Ahmad F, Harms M, Seale P, Manganiello V, Birnbaum MJ. The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin. Mol Cell Biol. 2015;35(16):2752-60.

13. Degerman E, Ahmad F, Chung YW, Guirguis E, Omar B, Stenson L, et al. From PDE3B to the regulation of energy homeostasis. Curr Opin Pharmacol. 2011;11(6):676-82.

14. Wilson LS, Baillie GS, Pritchard LM, Umana B, Terrin A, Zaccolo M, et al. A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3 kinase signals in human arterial endothelial cells. J Biol Chem. 2011;286(18):16285-96.

15. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187-96.

16. Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, et al. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry. 2004;43(20):6091-100.

17. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure. 2010;18(9):1083-93.

18. Yogosawa S, Mizutani S, Ogawa Y, Izumi T. Activin receptor-like kinase 7 suppresses lipolysis to accumulate fat in obesity through downregulation of peroxisome proliferator-activated receptor γ and C/EBPα. Diabetes. 2013;62(1):115-23.

19. Huse M, Chen YG, Massagué J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell. 1999;96(3):425-36.

20. Watkins HA, Chakravarthy M, Abhayawardana RS, Gingell JJ, Garelja M, Pardamwar M, et al. Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular Properties. J Biol Chem. 2016;291(22):11657-75.

21. Mistrova E, Wiegand S, Sviglerova J, Pfeil U, Kuncova J, Slavikova J, et al. Adrenomedullin and the calcitonin receptor-like receptor system mRNA expressions in the rat heart and sensory ganglia in experimentally-induced long-term diabetes. Gen Physiol Biophys. 2014;33(2):215-25.

22. Watkins HA, Walker CS, Ly KN, Bailey RJ, Barwell J, Poyner DR, et al. Receptor activitymodifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology. Br J Pharmacol. 2014;171(3):772-88.

23. Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. Proc Natl Acad Sci U S A. 2001;98(2):615-9.

24. Dackor RT, Fritz-Six K, Dunworth WP, Gibbons CL, Smithies O, Caron KM. Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol Cell Biol. 2006;26(7):2511-8.

25. Dong Y, Betancourt A, Belfort M, Yallampalli C. Targeting Adrenomedullin to Improve Lipid Homeostasis in Diabetic Pregnancies. J Clin Endocrinol Metab. 2017;102(9):3425-36.

26. Booe JM, Walker CS, Barwell J, Kuteyi G, Simms J, Jamaluddin MA, et al. Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor. Mol Cell. 2015;58(6):1040-52.

27